Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire?
- PMID: 29338083
- PMCID: PMC5885282
- DOI: 10.1002/cncr.31153
Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire?
Abstract
Androgen-deprivation therapy (ADT) remains the cornerstone of management for patients with metastatic prostate cancer. Although the toxicities of ADT are well established, there is increasing controversy surrounding the association between cognitive dysfunction and the receipt of ADT, with some evidence suggesting an increased risk of dementia. The authors conducted a literature search to identify pertinent clinical studies in this field. This general review outlines the key findings and discusses the relative strengths and weaknesses when drawing conclusions about the risk of cognitive dysfunction or dementia with ADT use. Cancer 2018;124:1326-34. © 2018 American Cancer Society.
Keywords: Alzheimer's dementia; androgen deprivation; cognitive dysfunction; dementia; prostate cancer.
© 2018 American Cancer Society.
Figures
Similar articles
-
Different androgen deprivation therapies might have a differential impact on cognition - An analysis from a population-based study using time-dependent exposure model.Cancer Epidemiol. 2020 Feb;64:101657. doi: 10.1016/j.canep.2019.101657. Epub 2020 Jan 7. Cancer Epidemiol. 2020. PMID: 31918180
-
Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician.Eur Urol Focus. 2020 Nov 15;6(6):1170-1179. doi: 10.1016/j.euf.2020.05.014. Epub 2020 Jul 18. Eur Urol Focus. 2020. PMID: 32690473 Review.
-
Androgen deprivation therapy for prostate cancer and risk of dementia.BJU Int. 2019 Jul;124(1):87-92. doi: 10.1111/bju.14666. Epub 2019 Feb 6. BJU Int. 2019. PMID: 30637900 Free PMC article.
-
Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis.Prostate Cancer Prostatic Dis. 2017 Sep;20(3):259-264. doi: 10.1038/pcan.2017.10. Epub 2017 Mar 28. Prostate Cancer Prostatic Dis. 2017. PMID: 28349979 Review.
-
Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.J Urol. 2018 Jun;199(6):1417-1425. doi: 10.1016/j.juro.2017.11.136. Epub 2018 Feb 2. J Urol. 2018. PMID: 29410294
Cited by
-
Analysis of androgen receptor expression and activity in the mouse brain.Sci Rep. 2024 May 15;14(1):11115. doi: 10.1038/s41598-024-61733-9. Sci Rep. 2024. PMID: 38750183 Free PMC article.
-
Impact of androgen deprivation therapy on cognitive function in men with prostate cancer.BJUI Compass. 2023 Dec 11;5(3):356-358. doi: 10.1002/bco2.319. eCollection 2024 Mar. BJUI Compass. 2023. PMID: 38481674 Free PMC article. No abstract available.
-
Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients' Real-World Insights for Optimizing Outcomes.Adv Ther. 2024 Feb;41(2):476-491. doi: 10.1007/s12325-023-02721-9. Epub 2023 Nov 18. Adv Ther. 2024. PMID: 37979089 Free PMC article. Review.
-
Cognitive Dysfunction in Patients Treated with Androgen Deprivation Therapy: A Multimodality Functional Imaging Study to Evaluate Neuroinflammation.Prostate Cancer. 2023 Oct 18;2023:6641707. doi: 10.1155/2023/6641707. eCollection 2023. Prostate Cancer. 2023. PMID: 37885823 Free PMC article.
-
Inequities in Definitive Treatment for Localized Prostate Cancer Among Those With Clinically Significant Mental Health Disorders.Urol Pract. 2023 Nov;10(6):656-663. doi: 10.1097/UPJ.0000000000000457. Epub 2023 Sep 26. Urol Pract. 2023. PMID: 37754206
References
-
- Barrass B, Thurairaja R, Persad R. More should be done to prevent the harmful effects of long term androgen ablation therapy in prostate cancer. BJU international. 2004;93(9):1175–6. - PubMed
-
- Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103(8):1615–24. - PubMed
-
- Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. The New England journal of medicine. 2009;360(24):2516–27. - PubMed
-
- Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. The Lancet Oncology. 2016;17(6):747–56. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical